TrialCancer2019

Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.

Hagop M Kantarjian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.